World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
100
Citations
42651
World Ranking
8200
National Ranking
4248

Overview

Ian E. Krop is affiliated with Harvard University in the United States and has contributed extensively to research in medicine and biochemistry, genetics, and molecular biology. Their scientific work predominantly focuses on oncology, with a particular emphasis on cancer research and treatment.

The main fields of study in Ian E. Krop's research include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

The subfields that characterize their research output comprise:

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research
  • Radiology, Nuclear Medicine and Imaging
  • Molecular Biology

Their work covers several specialized topics, including:

  • HER2/EGFR in Cancer Research
  • Advanced Breast Cancer Therapies
  • Cancer Treatment and Pharmacology
  • Breast Cancer Treatment Studies
  • Cancer Genomics and Diagnostics
  • Monoclonal and Polyclonal Antibodies Research
  • Brain Metastases and Treatment

Ian E. Krop has frequently published in notable scientific journals. The venues where they have a significant presence include:

  • Cancer Research
  • Journal of Clinical Oncology
  • Annals of Oncology
  • Clinical Cancer Research
  • UNC Libraries

Their recent papers illustrate their research focus and collaborative efforts. Some of the notable publications are:

  • Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study (2020), Journal of Clinical Oncology
  • TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes (2020), Journal of Clinical Oncology
  • Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up (2021), Journal of Clinical Oncology
  • Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors (2020), Cancer Discovery
  • Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial (2023), The Lancet

Collaborative relationships have played an important role in Ian E. Krop's research. Frequent co-authors include:

  • Eric P. Winer
  • Sara M. Tolaney
  • Nancy U. Lin
  • Antonio C. Wolff
  • Lisa A. Carey

Best Publications

  • Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

    Sunil Verma;David Miles;Luca Gianni;Ian E. Krop

  • 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

    F. Cardoso;A. Costa;E. Senkus;M. Aapro

  • Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

    Shanu Modi;Cristina Saura;Toshinari Yamashita;Yeon Hee Park

  • CDK4/6 inhibition triggers anti-tumour immunity

    Shom Goel;Molly J. DeCristo;April C. Watt;Haley BrinJones

  • Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.

    Rashmi K Murthy;Sherene Loi;Alicia Okines;Elisavet Paplomata

  • E2A proteins are required for proper B cell development and initiation of immunoglobulin gene rearrangements

    Gretchen Bain;Els C.Robanus Maandag;David J. Izon;Derk Amsen

  • Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

    Howard A. Burris;Hope S. Rugo;Svetislava J. Vukelja;Charles L. Vogel

  • Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis

    Romualdo Barroso-Sousa;William T. Barry;Ana C. Garrido-Castro;F. Stephen Hodi

  • Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.

    Sara M. Tolaney;William T. Barry;Chau T. Dang;Denise A. Yardley

  • ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)

    F. Cardoso;A. Costa;L. Norton;E. Senkus

  • Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

    Ian E Krop;Sung-Bae Kim;Antonio González-Martín;Patricia M LoRusso

  • Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer

    Ian E. Krop;Muralidhar Beeram;Shanu Modi;Suzanne F. Jones

  • Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.

    Shanu Modi;Haeseong Park;Rashmi K. Murthy;Hiroji Iwata

  • Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial

    Véronique Diéras;David Miles;Sunil Verma;Mark Pegram

  • Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer

    Shaokun Shu;Charles Y. Lin;Housheng Hansen He;Robert M. Witwicki

  • Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial

    Ian E Krop;Sung-Bae Kim;Antonio Gonzalez Martin;Patricia M LoRusso

  • A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine

    Ian E. Krop;Patricia LoRusso;Kathy D. Miller;Shanu Modi

  • 進行性乳癌のためのESO-ESMO国際コンセンサスガイドライン第四版(ABC 4)

    F Cardoso;E Senkus;A Costa;E Papadopoulos

  • Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib

    Lisa A. Carey;Donald A. Berry;Constance T. Cirrincione;William T. Barry

  • Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer

    Shaokun Shu;Charles Y. Lin;Housheng Hansen He;Robert M. Witwicki

Frequent Co-Authors

Eric P. Winer
Eric P. Winer Yale University
Sara M. Tolaney
Sara M. Tolaney Harvard University
Antonio C. Wolff
Antonio C. Wolff Johns Hopkins University
Lisa A. Carey
Lisa A. Carey University of North Carolina at Chapel Hill
Patricia LoRusso
Patricia LoRusso Yale University
Hope S. Rugo
Hope S. Rugo University of California, San Francisco
Kathy D. Miller
Kathy D. Miller Indiana University
Véronique Diéras
Véronique Diéras Institute Curie
Ann H. Partridge
Ann H. Partridge Harvard University
Kornelia Polyak
Kornelia Polyak Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in a career in Medicine but want flexible options or alternative pathways, a range of online nursing degrees can help you advance quickly and affordably. For those seeking advanced research or teaching roles, phd in nursing online programs offer a rigorous but flexible route to doctoral credentials, often at a lower cost than traditional on-campus programs.

Registered Nurses can accelerate their careers and boost their earning potential by pursuing the rn to bsn cheapest programs. These affordable online degrees are designed for working professionals looking to earn their BSN while managing work and family commitments.

If you have a non-nursing bachelor’s degree, direct entry msn programs for non nurses online provide a direct path to advanced nursing practice, granting an MSN and opening doors to specialized roles.

For aspiring nurses just starting out, direct admit nursing programs offer accessible entry points, sometimes with less competitive admissions for faster application cycles. Exploring these options can help you find the educational and career pathway that best fits your goals.

Best Scientists Citing Ian E. Krop

Trending Scientists

Recently Published Articles